PFE | Jotup

Thinking about trading options or stock in Twitter, Netflix, Apple, Advanced Micro Devices, or Pfizer?

Retrieved on:

Thursday, June 16, 2022

NFLX, Wall Street, AAPL, TWTR, AMD, PFE, Retail

NEW YORK, June 16, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TWTR, NFLX, AAPL, AMD, and PFE.

Key Points:

NEW YORK, June 16, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TWTR, NFLX, AAPL, AMD, and PFE.
Click a link below then choose between in-depth options trade idea report or a stock score report.
Options Report Ideal trade ideas on up to seven different options trading strategies.
The report shows all vital aspects of each option trade idea for each stock.

Akero Therapeutics Announces Two Financing Transactions with Pfizer Inc. and Hercules Capital, Inc. Providing Access to Up To $125 Million

Retrieved on:

Thursday, June 16, 2022

SOUTH SAN FRANCISCO, Calif., June 16, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced two financing transactions. The first is a $25 million equity investment by Pfizer Inc. (NYSE: PFE) at $9.90 per share. The second is a term loan facility providing Akero with access to up to $100 million from Hercules Capital, Inc. (NYSE: HTGC), of which $10 million will be drawn at transaction close. Together with existing cash, proceeds will support Akero’s continued development of efruxifermin (EFX), a long-acting analog of fibroblast growth factor 21 (FGF21), including two ongoing Phase 2b clinical trials in patients with pre-cirrhotic and cirrhotic nonalcoholic steatohepatitis (NASH); manufacture of a drug product-device combination for use in Phase 3 clinical trials; and starting a Phase 3 clinical trial program. If the term loan is fully drawn, proceeds from these two transactions together with budget optimization efforts are expected to fund Akero’s current operating plan until the third quarter of 2024. This extends Akero’s previously announced cash guidance by a full year (from the third quarter of 2023 to the third quarter of 2024), two years beyond the anticipated readout of the HARMONY study in the third quarter of this year.

Key Points:

The first is a $25 million equity investment by Pfizer Inc. (NYSE: PFE) at $9.90 per share.
The second is a term loan facility providing Akero with access to up to $100 million from Hercules Capital, Inc. (NYSE: HTGC), of which $10 million will be drawn at transaction close.
Pfizer has deep expertise and history in addressing health challenges that affect millions of patients around the world, including cardiometabolic diseases.
The $100 million term loan facility is being provided by Hercules Capital, a leader in customized specialty financing for life science companies.

Pfizer Completes Acquisition of ReViral

Retrieved on:

Thursday, June 9, 2022

Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of ReViral, a privately held, clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel antiviral therapeutics that target respiratory syncytial virus (RSV).

Key Points:

Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of ReViral, a privately held, clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel antiviral therapeutics that target respiratory syncytial virus (RSV).
ReViral brings to Pfizer a portfolio of promising therapeutic candidates, including sisunatovir, an orally administered inhibitor designed to block fusion of the RSV virus to the host cell.
Under the terms of the agreement, Pfizer acquired ReViral for a total consideration of up to $525 million, including upfront and development milestones.
In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News , LinkedIn , YouTube and like us on Facebook at Facebook.com/Pfizer .

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

Retrieved on:

Thursday, June 9, 2022

To view and listen to the webcast, visit our web site at www.pfizer.com/investors .

Key Points:

To view and listen to the webcast, visit our web site at www.pfizer.com/investors .
Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today.
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives.
Pfizer assumes no obligation to update forward-looking statements contained in the webcast as the result of new information or future events or developments.

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

Retrieved on:

Wednesday, June 8, 2022

To view and listen to the webcast, visit our web site at www.pfizer.com/investors .

Key Points:

To view and listen to the webcast, visit our web site at www.pfizer.com/investors .
Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today.
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives.
Pfizer assumes no obligation to update forward-looking statements contained in the webcast as the result of new information or future events or developments.

Rainier Partners Invests in Pet Food Express, a Fast-Growing Omni-Channel Pet Retailer

Retrieved on:

Wednesday, June 8, 2022

Home Goods, Other Retail, Pets, Finance, Professional Services, Online Retail, Consumer, Retail, PFE, Â, Growth, PETS, Adoption, Partnership, Partner, Organic, Volunteering, Pet Food Express, Bottled water

Rainier Partners, a Seattle-based, lower-middle-market private equity firm, is pleased to announce its investment in Pet Food Express (PFE), a fast-growing, omnichannel pet retailer that sells healthy pet foods, goods, and services from over 60 retail locations throughout California.

Key Points:

Rainier Partners, a Seattle-based, lower-middle-market private equity firm, is pleased to announce its investment in Pet Food Express (PFE), a fast-growing, omnichannel pet retailer that sells healthy pet foods, goods, and services from over 60 retail locations throughout California.
Rainier Partners is a private equity firm founded in 2020 and based in Seattle, WA, that invests in lower middle-market businesses.
Pet Food Express is California's trusted independent pet retailer, dedicated to helping pets live longer, healthier lives.
Founded by Michael Levy, Pet Food Express has reimagined pet care by focusing on the very best brands and products.

Pfizer Provides Update on Ownership Interest in Haleon

Retrieved on:

Wednesday, June 1, 2022

Pfizer Inc. (NYSE: PFE) today provided an update on its ownership interest in Haleon plc (Haleon), the newly independent company which will hold the joint Consumer Healthcare business of GSK plc (NYSE: GSK) and Pfizer following the demerger of approximately 80% of GSKs ownership interest in the business to GSKs shareholders.

Key Points:

Pfizer Inc. (NYSE: PFE) today provided an update on its ownership interest in Haleon plc (Haleon), the newly independent company which will hold the joint Consumer Healthcare business of GSK plc (NYSE: GSK) and Pfizer following the demerger of approximately 80% of GSKs ownership interest in the business to GSKs shareholders.
Following the demerger and listing of Haleon on the London Stock Exchange (LSE), which is expected to occur in July 2022, Pfizer will continue to hold a 32% ownership interest in Haleon.
Under the terms of the transaction, Pfizer and GSK received 32% and 68% ownership interests in the JV, respectively.
GSK and certain related entities will retain, in the aggregate, an approximately 13.6% ownership interest in Haleon following the transaction.

Pfizer Invites Public to View and Listen to a Webcast of Pfizer Discussion on Expanding Access & Affordability

Retrieved on:

Tuesday, May 31, 2022

To view and listen to the webcast, visit our web site at www.pfizer.com/investors .

Key Points:

To view and listen to the webcast, visit our web site at www.pfizer.com/investors .
In addition, information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today.
The transcript of the discussion will be made available on our website at www.pfizer.com/investors within 24 hours after the program.
Pfizer assumes no obligation to update forward-looking statements contained in the webcast as the result of new information or future events or developments.

Pfizer Granted FDA Fast Track Designation for Ervogastat/Clesacostat Combination for the Treatment of Non-Alcoholic Steatohepatitis (NASH)

Retrieved on:

Thursday, May 26, 2022

Research, Infectious Diseases, FDA, Clinical Trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Acetyl-CoA carboxylase, Disease, Food, Epidemiology, U.S. Securities and Exchange Commission, Lipid metabolism, Review, Liver, Acci, Non-alcoholic fatty liver disease, YouTube, EMA, Twitter, WP, Prevalence, Kidney, Epidemic, Clinical trial, COVID-19, Inc., Fatty liver disease, Research, Facebook, Type 2, ACC, Fast Track, NYSE, Digestive, Inflammation, Hospital, NASH, Enzyme, Science, Vaccine, FDA, Gastroenterology, Fibrosis, Internal medicine, Ageing, LinkedIn, PFE, Senior, Risk, Population, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, Obesity, Liver disease, Safety, National Institute of Diabetes and Digestive and Kidney Diseases, Cirrhosis, NAFLD, Acetyl-CoA, Rusyns, News, Pharmaceutical industry, Dietary supplement, Pfizer, Nature Medicine, Diabetes

Receiving Fast Track designation from the FDA reinforces Pfizers belief in ervogastat/clesacostat as a potential treatment for NASH, a serious, progressive liver disease with no currently approved therapies, said James Rusnak, M.D., Ph.D., Senior Vice President and Chief Development Officer, Internal Medicine and Hospital, Pfizer.

Key Points:

Receiving Fast Track designation from the FDA reinforces Pfizers belief in ervogastat/clesacostat as a potential treatment for NASH, a serious, progressive liver disease with no currently approved therapies, said James Rusnak, M.D., Ph.D., Senior Vice President and Chief Development Officer, Internal Medicine and Hospital, Pfizer.
The results of this study, which also includes arms investigating ervogastat as monotherapy, will inform a potential Phase 3 development program.
Diacylglycerol O-acyltransferase 2 (DGAT2) and acetyl-CoA carboxylase (ACC) are two key enzymes that regulate lipid metabolism.
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives.

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

Retrieved on:

Wednesday, May 25, 2022

To view and listen to the webcast, visit our web site at www.pfizer.com/investors .

Key Points:

To view and listen to the webcast, visit our web site at www.pfizer.com/investors .
Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today.
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives.
Pfizer assumes no obligation to update forward-looking statements contained in the webcast as the result of new information or future events or developments.